Lean body weight-adjusted intravenous iodinated contrast dose for abdominal CT in dogs reduces interpatient enhancement variability while providing diagnostic quality organ enhancement.

Contrast-enhanced computed tomography (CECT) is increasingly used to screen for abdominal pathology in dogs, and the contrast dose used is commonly calculated as a linear function of total body weight (TBW). Body fat is not metabolically active and contributes little to dispersing or diluting contrast medium (CM) in the blood. This prospective, analytic, cross-section design pilot study aimed to establish the feasibility of intravenous CM dosed according to lean body weight (LBW) for abdominal CECT in dogs compared to TBW. We hypothesized that when dosing intravenous CM according to LBW, studies will remain at diagnostic quality, there will be a reduced interindividual contrast enhancement (CE) variability, and there will be less change to heart rate and blood pressure in dogs compared to when administering CM calculated on TBW. Twelve dogs had two CECT studies with contrast doses according to TBW and LBW at least 8 weeks apart. Interindividual organ and vessel CE variability, diagnostic quality of the studies, and changes in physiological status were compared between protocols. The LBW-based protocol provided less variability in the CE of most organs and vessels (except the aorta). When dosed according to LBW, liver enhancement was positively associated with grams of iodine per kg TBW during the portal venous phase (P = 0.046). There was no significant difference in physiological parameters after CM administration between dosing protocols. Our conclusion is that a CM dose based on LBW for abdominal CECT lowers interindividual CE variability and is effective at maintaining studies of diagnostic quality.

Aorta, liver, and portal vein CT contrast enhancement during the portal venous phase are positively associated with abdominal fat percentage in dogs.

Contrast-enhanced computed tomography (CT) is increasingly being used as a standard diagnostic test for dogs with suspected abdominal pathology. The iodinated contrast dose is commonly calculated based on linear increases in total body weight. However, body fat is not metabolically active and contributes little to dispersing or diluting the contrast medium in the blood. The aim of this retrospective single-center analytic study was to investigate the possible correlation between abdominal organ and vessel enhancement, and abdominal fat percentage in dogs. We hypothesized that, when dosing intravenous iodinated contrast according to total body weight, there would be a positive association between the degree of contrast enhancement of selected organs and vessels with increasing abdominal fat percentage. Vascular and parenchymal attenuation data were collected from 62 multiphasic abdominal CECT scans performed on dogs over a 5-year period at U-Vet Werribee Animal Hospital between February 2014 and February 2019. Findings based on a linear regression model showed a positive association of aorta (P = .005), liver (P = .045), and portal vein (P = .001) enhancement to abdominal fat percentage during the portal venous phase. Authors recommend that other body size parameters, such as lean body weight, should be considered when calculating iodine dose for abdominal contrast-enhanced CT in dogs.